[1] PECOITS-FILHO R,ABENSUR H,BETÔNICO C C R,et al.Interactions between kidney disease and diabetes:dangerous liaisons[J].Diabetol Metab Syndr,2016,8:1-21.
[2] 中国中西医结合学会内分泌专业委员会糖尿病肾脏病专家委员会,中国微循环学会中医与微循环专业委员会.糖尿病肾脏病中西医结合防治专家共识(2023版)[J].中华糖尿病杂志,2023,15(8):690-702.
[3] 赵梦萍,孔祥栋,陈肖蓉,等.达格列净治疗早期糖尿病肾病的疗效及对血清TNF-α、IL-6水平的影响[J].中国现代医生,2022,60(14):33-36.
[4] AKHTAR M,TAHA N M,NAUMAN A,et al.Diabetic kidney disease:past and present[J].Adv Anat Pathol,2020,27(2):87-97.
[5] 柳晶.糖尿病肾病药物治疗的现状和进展[J].肾脏病与透析肾移植杂志,2022,31(5):470-474.
[6] 蔡春沉,王肃,谷优优.中西医治疗糖尿病肾病的研究现状[J].现代诊断与治疗,2022,33(4):486-488.
[7] 中国微循环学会糖尿病与微循环专业委员会,中华医学会糖尿病学分会教育与管理学组,中华医学会内分泌学分会基层内分泌代谢病学组,等.体医融合糖尿病运动干预专家共识[J].中华糖尿病杂志,2022,14(10):1035-1043.
[8] 中华医学会内分泌学分会.中国成人糖尿病肾脏病临床诊断的专家共识[J].中华内分泌代谢杂志,2015,31(5):379-385.
[9] SUGAHARA M,PAK W L W,TANAKA T,et al.Update on diagnosis,pathophysiology,and management of diabetic kidney disease[J].Nephrology,2021,26(6):491-500.
[10] TUTTLE K R,AGARWAL R,ALPERS C E,et al.Molecular mechanisms and therapeutic targets for diabetic kidney disease[J].Kidney Int,2022,102(2):248-260.
[11] 李佳佳,黄皓,陶立坚,等.糖尿病肾病主要发病机制的研究进展[J].生命科学,2023,35(3):396-404.
[12] 毕礼明,王朝晖.糖尿病肾病发病机制研究进展[J].内科理论与实践,2023,18(3):201-205.
[13] JUNG C Y,YOO T H.Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease[J].Diabetes Metab J,2022,46(2):181-197.
[14] 李慧灵,唐晨晨,申雨萍,等.糖尿病肾病发病机制与中西医治疗的研究进展[J].临床医学工程,2023,30(8):1175-1176.
[15] 党佳蓉,党琳慧,郭煦妍,等.糖尿病肾病的发病机制研究[J].医学信息,2022,35(17):161-165.
[16] WEI L,HAN Y,TU C.Molecular pathways of diabetic kidney disease inferred from proteomics[J].Diabetes Metab Syndr Obes,2023:117-128.
[17] RAYEGO-MATEOS S,RODRIGUES-DIEZ R R,FERNANDEZ-FERNANDEZ B,et al.Targeting inflammation to treat diabetic kidney disease:the road to 2030[J].Kidney Int,2023,103(2):282-296.
[18] 陈爽,全裕俊,董蓉,等.比较胰岛素样生长因子1受体抑制剂与胰岛素对2型糖尿病肾病小鼠肾间质巨噬细胞浸润的改善作用[J].中华肾脏病杂志,2019,35(10):765-772.
[19] SINGH J,JAIN A,BHAMRA R,et al.The mechanistic role of different mediators in the pathophysiology of nephropathy:a review[J].Current Drug Targets,2023,24(2):104-117.
[20] LIN H C,PENG C H,CHIOU J Y,et al.Physical activity is associated with decreased incidence of chronic kidney disease in type 2 diabetes patients:a retrospective cohort study in Taiwan[J].Prim Care Diabetes,2014,8(4):315-321.
[21] KOTAKE H,YAMADA S,OGURA Y,et al.Endurance exercise training-attenuated diabetic kidney disease with muscle weakness in spontaneously diabetic Torii fatty rats[J].Kidney Blood Press Res,2022,47(3):203-218.
[22] YANG P,ZHANG Y Y,ALIMAN R.Research progress of exercise improving dysfunction of islet beta cells[J].Chin J Cell Biol,2021,43(12):2402-2408.
[23] 郭宗承,蓝天,马路遥,等.运动改善糖尿病肾病作用机制研究进展[J].中国细胞生物学学报,2023,45(10):1568-1574.
[24] MALEK V,SURYAVANSHI S V,SHARMA N,et al.Potential of renin-angiotensin-aldosterone system modulations in diabetic kidney disease:old players to new hope![J].Rev Physiol Biochem Pharmacol,2021(179):31-71.
[25] 戴刘宴,张梅.运动干预糖尿病肾病的机制及应用研究进展[J].南京医科大学学报(自然科学版),2023,43(9):1307-1312.
[26] 中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏疾病防治临床指南[J].中华糖尿病杂志,2019,11(1):15-28.
[27] 徐扬,冯玫.运动处方在糖尿病患者中的应用进展[J].中华全科医师杂志,2021,20(8):902-906.
[28] RUSSO I,FRANGOGIANNIS N G.Diabetes-associated cardiac fibrosis:cellular effectors,molecular mechanisms and therapeutic opportunities[J].J Mol Cell Cardiol,2016,90:84-93.
[29] 胡晓蓉,李修英,许娟,等.高强度间歇运动联合抗阻运对2型糖尿病患者糖脂代谢的影响[J].中国卫生检验杂志,2023,33(12):1486-1489,1494.
[30] 陈素华,孙继红.有氧运动联合抗阻训练对2型糖尿病患者氧化应激及糖脂代谢的影响[J].罕少疾病杂志,2023,30(8):95-97.
[31] NAVARRO-GONZALEZ J F,MORA-FERNANDEZ C.The role of inflammatory cytokines in diabetic nephropathy[J].J Am Soc Nephrol,2008,19(3):433-442.
[32] WADA J,MAKINO H.Inflammation and the pathogenesis of diabetic nephropathy[J].Clin Sci,2013,124(3):139-152.
[33] 税晓平,李春莹,李顺昌,等.有氧和抗阻运动干预2型糖尿病大鼠骨骼肌脑源性神经营养因子、核因子κB及炎症指标的表达[J].中国组织工程研究,2022,26(5):669-675. |